Trial RPCEC00000338
Publication Pérez-Rodríguez S, medRxiv, 2021
Primary outcome on the report: The two co-primary outcomes, safety and reactogenicity, were assessed until 28 days after the third, last dose. Safety was measured by the occurrence of serious adverse events. Results of laboratory analyses on blood samples at 28 days after the last dose were compared to pre-vaccination values.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.